Highly selective, allosteric pan-Akt inhibitor (IC50 values are 8, 12 and 65 nM at Akt1, Akt2 and Akt3 respectively) which shows no inhibitory activity at 250 other protein kinases. Orally bioavailable and blood brain barrier permeable. Binds to Akt and inhibits it in a non-ATP competitive manner. Shows anti-cancer (antineoplastic) antiproliferative and anti-tumor activity. Synergistically inhibits cell proliferation of human cancer cell lines to enhance anti-tumor efficacy when used in combination with other anticancer agents. Induces cell cycle arrest, autophagy and apoptosis.
Solubility & Handling
Storage instructions
-20°C
Solubility overview
Soluble in DMSO (100 mM)
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
References are publications that support the biological activity of the product
eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H et al (2010) Molecular cancer therapeutics 9 : 1956-67
Understanding purity and quality - a guide for life scientists
